Medtronic stock faces valuation test after strong multi-year run

Medtronic stock is facing a valuation test after a strong multi-year advance. In an analysis published on Wednesday, November 11, 2026, Simply Wall St said the company’s cash-flow outlook broadly supported its share price, while cautioning that expectations for future growth are already important to the investment case.

Medtronic stock traded at 91.58 euros on Lang & Schwarz at 12:04 CET on Thursday, November 12, 2026, 0.64 percent above the Xetra close of Wednesday, November 11. The Xetra quote was 91.00 euros at 17:35:30 CET, according to Yahoo Finance.

Cash Flow Supports The Debate

Simply Wall St said Medtronic had generated 6.1 billion US dollars in free cash flow over the latest twelve months. Its discounted cash-flow model indicated that the company’s share price was broadly in line with the cash flows it expected the business to generate, framing Medtronic as a mature, cash-generative healthcare company rather than a high-risk turnaround.

The analysis also pointed to a price-to-earnings ratio of 23.8 as a separate valuation reference. Its growth case rests on higher-growth cardiovascular and robotics platforms, alongside investments in renal denervation, pelvic neuromodulation, structural heart and neurovascular therapies. A more cautious scenario described the stock as 12 percent overvalued, underscoring the sensitivity of the valuation to execution and future cash-flow growth.

Products And Results Ahead

Recent attention has centered on Medtronic’s Symplicity Spyral renal denervation system and a broader FDA evidence label. The company has also expanded its neurovascular portfolio with the Aristotle Mini Guidewire, adding product developments to the group of factors investors may weigh before the next financial update.

Medtronic has scheduled its fiscal second-quarter 2027 results for Tuesday, November 24, 2026. The report will give investors a fresh reference point for revenue growth, cash generation and management’s view of the company’s product pipeline.

The S&P 500 provides the broader market backdrop for US-listed healthcare shares.

More news and analyses on Medtronic stock